L'oreal

Societe L'oreal Sa

Michel Kermici

Dominique Bernard

Michel Prunieras

Marie-Alix Bernard-Bourboulon

Francis Pruche

Joel Brod

Isolated, substantially pure natural or synthetic polypeptides comprising cathepsin L type cysteine proteases, or polypeptide fragments or polypeptide admixtures obtained via proteolysis thereof, are useful for reducing intercorneocyte cohesion and, thus, for promoting desquamation.

Isolated cathepsin L type cysteine proteases and reducing intercorneocyte cohesion/promoting desquamation therewith

A cathepsin L type cysteine protease has been isolated from the healthy stratum corneum of human skin. The protease has a pH optimum of 5 to 5.5 and mass of about 28 kDa.

Method for diagnosing cellular aging or inflammation condition of

This biosensor comprises a membrane (8), in which an enzyme catalyzing the transformation of a substrate used in the cutaneous metabolism is immobilized, means for detecting and measuring a phenomenon caused by said transformation, which is representative of the concentration of the substrate to be measured, with said substrate being brought into contact with the enzymatic membrane (8), and a measuring cell (13), a wall area of which is formed by the membrane (8) and which is capable of being closed, during the measurement, by a cutaneous covering area (15), with the cell (13) being combined with means for making circulate therein a liquid for placing in solution the substrate to be measured. For the measurement, the biosensor is applied to the skin, the buffer is injected into the cell and, once said cell is filled, the detection and the measurement are carried out, then the buffer is again made to circulate in order to remove the solubilized substrate. This measuring cycle can be repeated without removing the electrode (1). The biosensor is used for measurement of cutaneous L-lactate with a Clark electrode combined with a membrane using L-lactate oxidase.

Method for the direct measurement of at least one chemical parameter of

A pharmaceutical composition for the treatment and prevention of erythma and acne comprises in a pharmaceutically acceptable carrier from about 1 to 10 weight percent based on the total weight of the composition of a delipidized and purified keratin polymer obtained from animal starting material containing keratin, the keratin polymer being in the free state.

Growing community of inventors

Paris, France

Michel Kermici